Lineage Cell Therapeutics, Inc. Accumulated Other Comprehensive Income
Lineage Cell Therapeutics, Inc. (LCTX) had Accumulated Other Comprehensive Income of -$4.47 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent › Accumulated Other Comprehensive Income (Loss), Net of Tax
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$4.47M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$3.97M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$3.92M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$4.29M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$4.47M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$3.97M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | -$3.92M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$4.29M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$4.10M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$2.68M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$2.88M 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$2.89M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$2.47M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$2.77M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$3.07M 10-K · filed 2025-03-10 | |
| 2023-09-30 | -$2.08M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$2.61M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$3.11M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$3.57M 10-K · filed 2024-03-07 | |
| 2022-09-30 | -$3.18M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$3.36M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$5.09M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$5.21M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$3.43M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$3.05M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$2.09M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$3.67M 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$821.00K 10-Q · filed 2020-11-04 | |
| 2020-06-30 | -$486.00K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $634.00K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$681.00K 10-K · filed 2021-03-11 | |
| 2019-09-30 | -$357.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $207.00K 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $694.00K 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $1.43M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $1.17M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $1.08M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $198.00K 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $451.00K 10-K · filed 2019-03-14 | |
| 2017-09-30 | $141.00K 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $271.00K 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $408.00K 10-Q · filed 2017-05-10 | |
| 2016-12-31 | -$738.00K 10-K · filed 2018-03-15 | |
| 2016-09-30 | -$690.00K 10-Q · filed 2016-11-04 | |
| 2016-06-30 | -$504.00K 10-Q · filed 2016-08-09 | |
| 2016-03-31 | -$60.00K 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$237.00K 10-K · filed 2017-03-16 | |
| 2015-09-30 | -$87.00K 10-Q · filed 2015-11-09 | |
| 2015-06-30 | -$131.00K 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $238.82K 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $186.00K 10-K · filed 2016-03-15 | $185.84K 10-K · filed 2015-03-11 |
| 2014-09-30 | -$150.69K 10-Q · filed 2014-11-07 | |
| 2014-06-30 | -$85.13K 10-Q · filed 2014-08-11 | |
| 2014-03-31 | -$44.34K 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $62.90K 10-K · filed 2015-03-11 | |
| 2013-09-30 | $124.74K 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $117.72K 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $88.87K 10-Q · filed 2013-05-10 | |
| 2012-12-31 | -$59.57K 10-K · filed 2014-03-17 | |
| 2012-09-30 | -$197.38K 10-Q · filed 2012-11-09 | |
| 2012-06-30 | -$181.61K 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $1.34K 10-Q · filed 2012-05-10 | |
| 2011-12-31 | -$122.75K 10-K · filed 2013-03-18 | |
| 2011-09-30 | -$99.49K 10-Q · filed 2011-11-08 | |
| 2011-06-30 | -$701.20K 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $897.34K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |